Surgalign Stock Forecast, Price & News

Surgalign (NASDAQ:SRGA) Frequently Asked Questions

Is Surgalign a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Surgalign in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Surgalign stock.
View analyst ratings for Surgalign or view top-rated stocks.

Are investors shorting Surgalign?

Surgalign saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 3,680,000 shares, a decrease of 33.5% from the October 31st total of 5,530,000 shares. Based on an average daily volume of 2,710,000 shares, the days-to-cover ratio is currently 1.4 days.
View Surgalign's Short Interest.

When is Surgalign's next earnings date?

Surgalign is scheduled to release its next quarterly earnings announcement on Tuesday, March 15th 2022.
View our earnings forecast for Surgalign.

How were Surgalign's earnings last quarter?

Surgalign Holdings, Inc. (NASDAQ:SRGA) released its earnings results on Tuesday, November, 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.03. The business had revenue of $20.55 million for the quarter, compared to the consensus estimate of $22.55 million. Surgalign had a negative net margin of 146.88% and a negative trailing twelve-month return on equity of 128.61%. During the same period last year, the firm posted ($0.11) EPS.
View Surgalign's earnings history.

What guidance has Surgalign issued on next quarter's earnings?

Surgalign issued an update on its FY 2021 earnings guidance on Tuesday, December, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $88 million-$92 million, compared to the consensus revenue estimate of $96.05 million.

What price target have analysts set for SRGA?

5 equities research analysts have issued 1 year price objectives for Surgalign's shares. Their forecasts range from $1.50 to $4.00. On average, they expect Surgalign's stock price to reach $3.15 in the next twelve months. This suggests a possible upside of 308.0% from the stock's current price.
View analysts' price targets for Surgalign or view top-rated stocks among Wall Street analysts.

Who are Surgalign's key executives?

Surgalign's management team includes the following people:

• Terry M. Rich, President, Chief Executive Officer & Director (LinkedIn Profile)
• G. Bryan Cornwall, EVP-Research & Clinical Affairs
• Douglas S. Bireley, Executive VP-Marketing, Research & Development
• Bob Watkins, Chief Information & Technology Officer
• Chris Thunander, Chief Accounting Officer & Vice President

Who are some of Surgalign's key competitors?

Some companies that are related to Surgalign include Sientra (SIEN), Eargo (EAR), Sanara MedTech (SMTI), Conformis (CFMS), Lakeland Industries (LAKE), United Health Products (UEEC), Milestone Scientific (MLSS), CollPlant Biotechnologies (CLGN), Invacare (IVC), ReWalk Robotics (RWLK), Alpha Pro Tech (APT), Predictive Oncology (POAI), Myomo (MYO), Bone Biologics (BBLG) and Nutriband (NTRB).
View all of SRGA's competitors.

What is Surgalign's stock symbol?

Surgalign trades on the NASDAQ under the ticker symbol "SRGA."

Who are Surgalign's major shareholders?

Surgalign's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Krensavage Asset Management LLC (4.55%), Eversept Partners LP (2.52%), Dimensional Fund Advisors LP (2.49%), Assenagon Asset Management S.A. (2.03%), Mitsubishi UFJ Kokusai Asset Management Co. Ltd. (1.34%) and Morgan Stanley (0.98%). Company insiders that own Surgalign stock include Mark Stolper, Nicholas J Valeriani, Terry M Rich, Thomas Mceachin and William Scott Durall.
View institutional ownership trends for Surgalign.

Which major investors are selling Surgalign stock?

SRGA stock was sold by a variety of institutional investors in the last quarter, including TownSquare Capital LLC, Millennium Management LLC, Morgan Stanley, Dimensional Fund Advisors LP, Goldman Sachs Group Inc., Eversept Partners LP, Mitsubishi UFJ Kokusai Asset Management Co. Ltd., and Verition Fund Management LLC.
View insider buying and selling activity for Surgalign or view top insider-selling stocks.

Which major investors are buying Surgalign stock?

SRGA stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Fuller & Thaler Asset Management Inc., Two Sigma Investments LP, UBS Group AG, Dfpg Investments LLC, Two Sigma Advisers LP, Geode Capital Management LLC, and HighTower Advisors LLC. Company insiders that have bought Surgalign stock in the last two years include Mark Stolper, Nicholas J Valeriani, Terry M Rich, Thomas Mceachin, and William Scott Durall.
View insider buying and selling activity for Surgalign or or view top insider-buying stocks.

How do I buy shares of Surgalign?

Shares of SRGA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Surgalign's stock price today?

One share of SRGA stock can currently be purchased for approximately $0.77.

How much money does Surgalign make?

Surgalign has a market capitalization of $107.46 million and generates $101.75 million in revenue each year. The company earns $-33.78 million in net income (profit) each year or ($1.63) on an earnings per share basis.

How many employees does Surgalign have?

Surgalign employs 197 workers across the globe.

What is Surgalign's official website?

The official website for Surgalign is www.surgalign.com.

Where are Surgalign's headquarters?

Surgalign is headquartered at 520 LAKE COOK ROAD SUITE 315, DEERFIELD IL, 60015.

How can I contact Surgalign?

Surgalign's mailing address is 520 LAKE COOK ROAD SUITE 315, DEERFIELD IL, 60015. The company can be reached via phone at (224) 303-4651, via email at [email protected], or via fax at 386-418-0342.